The trial will enroll participants into three cohorts by dose level who will be randomized 4:1 to BNT165b1:placebo. The trial will use a staggered dose escalation schema with sentinel participants for Dose 1 in all cohorts.
This first-in-human clinical trial, is a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, an ribonucleic acid (RNA)-lipid nanoparticle (LNP) encoding for part of the Plasmodium falciparum circumsporozoite protein (PfCSP).~BNT165b1 will be evaluated at three dose levels (DLs) to select a safe and tolerable dose in a 3-dose schedule.